Criteria for NGS testing in MNs can reduce unnecessary tests, saving costs without affecting patient care quality. Six approval and six cancellation criteria guide appropriate NGS use, focusing on ...

Using iPS cells generated from a patient with a myeloid neoplasm caused by a rare chromosomal rearrangement between the MECOM and MYC genes, a team of researchers led by Associate Professor Yoshinori ...

For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant. While autologous ...

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Therapy-related myeloid neoplasm (t-MN) ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Researchers found JAK-STAT mutations in a predominance of a cohort of adults with fusion-free ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell (PBSC) transplantation for non-Hodgkin lymphoma (NHL). Previous studies report an ...